Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571036 | 0.90 | CES1 (0.73) | MAPTCA1CA2MEN1KMT2A | |
| SCHEMBL4001627 | 0.88 | IDH1 (0.67) | IDH1MAPTCA12CA1CA2 | |
| SCHEMBL9488026 | 0.88 | CNR2 (0.61) | IDH1MAPTCA12CA1CA2 | |
| SCHEMBL12010881 | 0.88 | MEN1 (0.68) | IDH1MAPTCA12CA1CA2 | |
| SCHEMBL12010912 | 0.86 | NR1H3 (0.68) | IDH1MAPTCA12CA1CA2 | |
| SCHEMBL4922162 | 0.85 | EPHX2 (0.81) | IDH1MAPTCA12CA1CA2 | |
| SCHEMBL14601685 | 0.82 | MEN1 (0.65) | MAPTCA1CA2MEN1KMT2A | |
| SCHEMBL15647764 | 0.82 | IDH1 (1.00) | IDH1 | |
| SCHEMBL2942043 | 0.82 | RORA (0.74) | MEN1KMT2ACES1 | |
| SCHEMBL15496614 | 0.82 | IDO1 (0.75) | IDH1MAPTCA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2068857-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| EP-2068857-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | IDH1 1860/4885MAPT 4737/4885CA12 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.